Articles from LAPIX Therapeutics Inc

LAPIX Therapeutics Announces First Patient Dosed in Phase Ib Study of LPX-TI641 in Atopic Dermatitis

Study Evaluates New Oral Capsule Formulation in a Th2-Dominant Inflammatory Disease

By LAPIX Therapeutics Inc · Via GlobeNewswire · December 23, 2025